Overview

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and tolerability of single rising doses of ASP2151 under fasted condition in healthy male subjects. The study will also evaluate the pharmacokinetics (PK) of a single dose of ASP2151 under fasted versus fed conditions in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Europe Ltd.